Difference between revisions of "Team:SDU CHINA"

Line 1: Line 1:
−
{{SDU_CHINA}}
 
−
<html>
 
  
  
−
<div class="column full_size" >
+
<html>
−
<img src="http://placehold.it/2000x300/d3d3d3/f2f2f2">
+
<head>
−
</div>
+
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
 +
<title>SDU_CHINA</title>
 +
<style>
 +
.bottom{position:relative}
 +
.bottom .bar{width:100%;height:50px;top:0;background-color:#72616e;position:absolute;;z-index:2;font-family:"Comic Sans MS", cursive}
 +
.bottom .square {width: 160px; height:160px; background:#e54b4b;position:absolute;z-index:2;top:0;left:40px;}
 +
.bottom .rectangle {width:1000px; height:100px; background:#19548f;position:absolute;z-index:0;top:160px;left:40px;}
 +
.bottom .logo{z-index:3;top:10px;left:50px;position:absolute;}
 +
.bottom .farewell{letter-spacing:3px;top:20px;left:40px;position:relative;font-size:50px;color:white;font-family:Verdana, Geneva, sans-serif}
  
 +
.menuDiv {
 +
        overflow: hidden;
 +
        display:inline-block;
 +
        padding-left:200px;
 +
float:left;
 +
margin-right:20px;
 +
z-index:2;
 +
font-size:30px
 +
font-family:Tahoma, Geneva, sans-serif}
 +
 +
.menuDiv a{text-decoration: none;}
 +
.menuDiv ul,.menuDiv li {
 +
        list-style: none;
 +
        padding: 0;
 +
        float: right;}
 +
.menuDiv > ul > li > ul {
 +
        position: absolute;
 +
        display: none;}
 +
.menuDiv > ul > li > ul > li {
 +
        float: none;}
 +
.menuDiv > ul > li:hover ul {
 +
        display: block;}
 +
.menuDiv > ul > li > a {
 +
        width:100px;
 +
        margin-top:-4px;
 +
        line-height:50px;
 +
        color: white;
 +
        background-color: #72616e;
 +
        text-align: center;
 +
        border-left: none;
 +
        display: block;
 +
font-size:18px;
 +
    }
 +
.menuDiv > ul > li:first-child > a {
 +
        border-left: none;
 +
    }
 +
.menuDiv > ul > li > a:hover {
 +
        color: #966;
 +
        background-color: #999;
 +
    }
 +
.menuDiv > ul > li > ul > li > a {
 +
        width: 150px;
 +
font-size:18px;
 +
        line-height: 50px;
 +
        color: white;
 +
        background-color:#72616e;
 +
        text-align: center;
 +
        border:none;
 +
        display: block;
 +
margin-left:-40px;
 +
    }
 +
.menuDiv > ul > li > ul > li:first-child > a {
 +
        border-top:no;
 +
    }
  
 +
.menuDiv > ul > li > ul > li > a:hover {
 +
        color:#966;
 +
        background-color:  #999;
 +
    }
 +
 
 +
.abstract{margin:0 10% auto 10% ;position:relative;padding-top:200px;}
 +
.abstract .title{position:relative;margin:0 auto auto 0;color:#660;font-family:Arial, Helvetica, sans-serif;font-size:30px}
 +
.abstract .content{top:10px;position:relative;letter-spacing:0.5px;font-family:"Palatino Linotype", "Book Antiqua", Palatino, serif, Times, serif;font-size:20px;word-break:break-all}
 +
.abstract .icon{position:relative;margin:0px auto}
 +
.abstract .subicon{position:relative;float:left;margin-left:100px}
  
−
<div class="column full_size" >
+
.foot{width:100%;height:200px;background:#0066CC;position:fixed"}
−
<h1> Welcome to iGEM 2017! </h1>
+
</style>
−
<p>Your team has been approved and you are ready to start the iGEM season! </p>
+
</head>
−
</div>  
+
<body>
 +
<div class="bottom">
 +
    <div class="bar">
 +
    <div class="menuDiv">
 +
        <ul>
 +
            <li>
 +
                <a href="#">Home</a> </li>
 +
            <li>
 +
                <a href="#">Project</a>
 +
                <ul>
 +
                    <li><a href="#">Description</a></li>
 +
                    <li><a href="#">Design</a></li>
 +
                    <li><a href="#">Experiment</a></li>
 +
                    <li><a href="#">Results</a></li>
 +
                    <li><a href="#">Notebook</a></li>
 +
                </ul>
 +
            </li>
 +
            <li>
 +
                <a href="#">Model</a>
 +
            </li>
 +
            <li>
 +
                <a href="#">Interlab</a>
 +
            </li>
 +
            <li>
 +
                <a href="#">Parts</a>
 +
                <ul>
 +
                    <li><a href="#">Basic parts</a></li>
 +
                    <li><a href="#">Composite parts</a></li>
 +
                </ul>
 +
            </li>
 +
            <li>
 +
                <a href="#">Practice</a>
 +
                <ul>
 +
                    <li><a href="#">Public education</a></li>
 +
                    <li><a href="#">Society activity</a></li>
 +
                </ul>
 +
            </li>
 +
            <li>
 +
                <a href="#">Awards</a>
 +
            </li>
 +
        </ul>
 +
    </div>
 +
    </div>
 +
    <div class="square"></div>
 +
    <div  class="logo"><img src="https://static.igem.org/mediawiki/2017/4/40/LOGO.png" style="width:140px;height:140px;"></div>
 +
    <div><img src="https://static.igem.org/mediawiki/2017/d/d6/SDU_main_title.png" style="z-index:0;width:60%;top:100px;left:300px;position:relative;z-index:1"></div>
 +
    <div><img src="https://static.igem.org/mediawiki/2017/a/ab/SDU_home_keyboard.png" style="width:60%;position:relative;top:120px;left:250px"></div>
 +
</div>、
  
−
<div class="clear"></div>
+
<div class="abstract" >
−
 
+
    <div class="title"><b>Abstract</b></div>
−
<div class="column half_size" >
+
    <div class="content"><p>Non-small cell lung cancer (NSCLC) is the
−
<h5>Before you start: </h5>
+
    leading cause of cancer-related death among the world with low
−
<p> Please read the following pages:</p>
+
    overall survival rate. In NSCLC, immunotherapy has been indicated
−
<ul>
+
      as a potential therapy for treating in situ solid tumor. Previous
−
<li>  <a href="https://2017.igem.org/Competition">Competition Hub</a> </li>
+
      research has indicated that tumor cells can express programmed
−
<li> <a href="https://2017.igem.org/Competition/Deliverables/Wiki">Wiki Requirements page</a></li>
+
      death-1 ligand (PD-L1) to diminish T-cell effector functions and
−
<li> <a href="https://2017.igem.org/Resources/Template_Documentation">Template documentation</a></li>
+
        therefore to achieve immune escape. In our project, gene edition
−
</ul>
+
        will be incorporated with immunotherapy to eradicate the immune
 +
        escape occurred in NSCLC. By constructing plasmid with
 +
        Crispr-Cas 9 system targeting the gene coding for PD-L1, the
 +
          expression of PD-L1 will be inhibited to restore immune system
 +
          supervision. To ensure the biosafety, another plasmid with
 +
          Crsipr-Cas 9 system to cut off the housekeeping gene of two
 +
          plasmids will be also constructed to suicide both plasmid when
 +
            PD-L1 expression was not detectable. Better therapeutic effects of
 +
            immunotherapy to conquer the NSCLC are hoped to be achieved.</p></div>
 
</div>
 
</div>
  
−
<div class="column half_size" >
+
<br> <br> <br> <br> <br> <br> <br> <br>
−
<div class="highlight">
+
−
<h5> Project Abstract </h5>
+
−
<p>Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death among the world with low overall survival rate. In NSCLC, immunotherapy has been indicated as a potential therapy for treating in situ solid tumor. Previous research has indicated that tumor cells can express programmed death-1 ligand (PD-L1) to diminish T-cell effector functions and therefore to achieve immune escape. In our project, gene edition will be incorporated with immunotherapy to eradicate the immune escape occurred in NSCLC. By constructing plasmid with Crispr-Cas 9 system targeting the gene coding for PD-L1, the expression of PD-L1 will be inhibited to restore immune system supervision. To ensure the biosafety, another plasmid with Crsipr-Cas 9 system to cut off the housekeeping gene of two plasmids will be also constructed to suicide both plasmid when PD-L1 expression was not detectable. Better therapeutic effects of immunotherapy to conquer the NSCLC are hoped to be achieved.
+
−
</p>  
+
−
</div>
+
−
</div>
+
  
−
<div class="column full_size" >
 
−
<h5> Wiki template information </h5>
 
−
<p>We have created these wiki template pages to help you get started and to help you think about how your team will be evaluated. You can find a list of all the pages tied to awards here at the <a href="https://2017.igem.org/Judging/Pages_for_Awards">Pages for awards</a> link. You must edit these pages to be evaluated for medals and awards, but ultimately the design, layout, style and all other elements of your team wiki is up to you!</p>
 
−
 
−
</div>
 
−
 
−
 
−
 
−
 
−
<div class="column half_size" >
 
−
<h5> Editing your wiki </h5>
 
−
<p>On this page you can document your project, introduce your team members, document your progress and share your iGEM experience with the rest of the world! </p>
 
−
<p> <a href="https://2017.igem.org/wiki/index.php?title=Team:Example&action=edit"> </a>Use WikiTools - Edit in the black menu bar to edit this page</p>
 
  
 +
<div>
 +
  <div class="foot">
 +
  </div>
 
</div>
 
</div>
  
−
 
+
</body>
−
<div class="column half_size" >
+
−
<h5>Tips</h5>
+
−
<p>This wiki will be your team’s first interaction with the rest of the world, so here are a few tips to help you get started: </p>
+
−
<ul>
+
−
<li>State your accomplishments! Tell people what you have achieved from the start. </li>
+
−
<li>Be clear about what you are doing and how you plan to do this.</li>
+
−
<li>You have a global audience! Consider the different backgrounds that your users come from.</li>
+
−
<li>Make sure information is easy to find; nothing should be more than 3 clicks away.  </li>
+
−
<li>Avoid using very small fonts and low contrast colors; information should be easy to read.  </li>
+
−
<li>Start documenting your project as early as possible; don’t leave anything to the last minute before the Wiki Freeze. For a complete list of deadlines visit the <a href="https://2017.igem.org/Calendar">iGEM 2017 calendar</a> </li>
+
−
<li>Have lots of fun! </li>
+
−
</ul>
+
−
</div>
+
−
 
+
−
 
+
−
<div class="column half_size" >
+
−
<h5>Inspiration</h5>
+
−
<p> You can also view other team wikis for inspiration! Here are some examples:</p>
+
−
<ul>
+
−
<li> <a href="https://2014.igem.org/Team:SDU-Denmark/"> 2014 SDU Denmark </a> </li>
+
−
<li> <a href="https://2014.igem.org/Team:Aalto-Helsinki">2014 Aalto-Helsinki</a> </li>
+
−
<li> <a href="https://2014.igem.org/Team:LMU-Munich">2014 LMU-Munich</a> </li>
+
−
<li> <a href="https://2014.igem.org/Team:Michigan"> 2014 Michigan</a></li>
+
−
<li> <a href="https://2014.igem.org/Team:ITESM-Guadalajara">2014 ITESM-Guadalajara </a></li>
+
−
<li> <a href="https://2014.igem.org/Team:SCU-China"> 2014 SCU-China </a></li>
+
−
</ul>
+
−
</div>
+
−
 
+
−
<div class="column half_size" >
+
−
<h5> Uploading pictures and files </h5>
+
−
<p> You can upload your pictures and files to the iGEM 2017 server. Remember to keep all your pictures and files within your team's namespace or at least include your team's name in the file name. <br />
+
−
When you upload, set the "Destination Filename" to <br><code>T--YourOfficialTeamName--NameOfFile.jpg</code>. (If you don't do this, someone else might upload a different file with the same "Destination Filename", and your file would be erased!)<br><br>
+
−
 
+
−
<a href="https://2017.igem.org/Special:Upload">
+
−
UPLOAD FILES
+
−
</a>
+
−
</p>
+
−
</div>
+
−
 
+
−
 
+
−
 
+
−
 
+
−
 
+
−
 
+
−
 
+
 
</html>
 
</html>

Revision as of 07:23, 4 September 2017


SDU_CHINA

、
Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death among the world with low overall survival rate. In NSCLC, immunotherapy has been indicated as a potential therapy for treating in situ solid tumor. Previous research has indicated that tumor cells can express programmed death-1 ligand (PD-L1) to diminish T-cell effector functions and therefore to achieve immune escape. In our project, gene edition will be incorporated with immunotherapy to eradicate the immune escape occurred in NSCLC. By constructing plasmid with Crispr-Cas 9 system targeting the gene coding for PD-L1, the expression of PD-L1 will be inhibited to restore immune system supervision. To ensure the biosafety, another plasmid with Crsipr-Cas 9 system to cut off the housekeeping gene of two plasmids will be also constructed to suicide both plasmid when PD-L1 expression was not detectable. Better therapeutic effects of immunotherapy to conquer the NSCLC are hoped to be achieved.